Aethlon Medical (NASDAQ:AEMD) Releases Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Aethlon Medical (NASDAQ:AEMD) posted its earnings results on Thursday. The medical equipment provider reported ($2.60) EPS for the quarter, beating analysts’ consensus estimates of ($2.91) by $0.31, FiscalAI reports.

Aethlon Medical Stock Up 0.9%

NASDAQ:AEMD traded up $0.05 on Thursday, hitting $5.58. The stock had a trading volume of 20,694 shares, compared to its average volume of 797,152. Aethlon Medical has a 1-year low of $1.41 and a 1-year high of $25.66. The company has a fifty day moving average price of $4.98 and a two-hundred day moving average price of $7.45. The stock has a market cap of $3.97 million, a price-to-earnings ratio of -0.16 and a beta of 1.27.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AEMD shares. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, October 17th. HC Wainwright restated a “neutral” rating on shares of Aethlon Medical in a research report on Friday, September 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $1.50.

About Aethlon Medical

Aethlon Medical, Inc. is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles. The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.